The present invention relates to compounds of general formulaI, wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.本發明係關於通式I化合物, 其中基團R、R1、R2、R3、m及n係如技術方案1中所定義,該等化合物具有有價值之藥理學性質,尤其結合至GPR40受體並調節其活性。該等化合物適於治療並預防會受此受體影響之疾病,例如代謝性疾病、尤其2型糖尿病。此外,本發明係關於新穎中間體,其可用於合成式I化合物。